RESEARCH PAPER
Comparison of the efficacy of dexketoprofen and diclofenac in treatment of non-specific low back pain
| 1 | Outpatient Pain Clinic, Institute of Rural Health, Lublin, Poland |
| 2 | Department of Pain Treatment and Palliative Care, Jagiellonian University, Collegium Medicum, Cracow, Poland |
CORRESPONDING AUTHOR
Krzysztof Brzeziński
Institute of Rural Health, Jaczewskiego 2, 20-090 Lublin, Poland
Institute of Rural Health, Jaczewskiego 2, 20-090 Lublin, Poland
Ann Agric Environ Med. 2013;20(Special Issue 1):52–56
KEYWORDS
ABSTRACT
Work-related loads, improper lifestyle, increasing obesity, and lack of adequate prophylaxy render low back pain (LBP) one of the most common causes of chronic pain worldwide.
Objective. The aim of the study was to compare the effect of two analgesic drugs on the effectiveness of therapy measured by pain intensity. and the degree of disability during treatment of chronic low back pain syndrome
Material and method. The retrospective analysis involved 185 patients undergoing treatment for chronic low back pain syndrome with dexketoprofen (DEX) and diclofenac (DIC). Patients’ gender. place of residence. cause of the pain as well as pain intensity in the visual-analogue scale (VAS) and the disability degree (Oswestry Disability Index – ODI) were analysed.
Results. From the first week of treatment to the end of the observation. the DEX group exhibited significantly lower values of pain intensity on the disability index. The correlation coefficients between the parameters were significantly higher in the DEX group. Analysis of variance demonstrated that the choice of NSAIDs was the most significant factor determining the effectiveness of the treatment.
Discussion. The cause of the pain and place of residence did not have any impact on the treatment efficacy. The pharmacological properties of dexketoprofen contribute to its beneficial effect on the therapy used. which validates the potential use of DEX in LBP management.
Summary. The significantly increased correlation between the aforementioned parameters suggests that administration of dexketoprofen in the management of non-specific low back pain results in a more rapid return to full physical activity and therefore more prompt return to work
REFERENCES (48)
1.
Kocot-Kępska M, Dobrogowski J. Ocena badań epidemiologicznych dotyczących bólu nienowotworowego prowadzonych w Europie w 2002 roku przez Mundipharma. Ból 2004; 5: 18–25 (in Polish).
2.
Riddle DL. Classification and low back pain: a review of the literature and critical analysis of selected systems. Physical Therapy 1998; 78: 708–737.
3.
Roland M, Fairbank J. The Roland-Morris Disability Questionnaire and the Oswestry Disability Index. Spine 2000; 25: 3115–3124.
4.
Skovron ML. Epidemiology of low back pain. Baillieres Clin Rheumatol. 1992; 6: 559–573.
5.
Suchorzewski M. Epidemiologia bólu kręgosłupa lędźwiowokrzyżowego w Polsce. Ból 2004; 5: 44.
6.
Cook AJ, Chastain DC. The classification of patients with chronic pain: age and sex differences. Pain Res Manag. 2001; 6: 142–151.
7.
MattilaVM, Saari L, Parikkari Jari, Koivusilta L, Rimpela A. Predictors of low back pain hospitalisztion – A prospecyive follow-up of 57,408 adolescents. Pain 2008; 139: 209–217.
8.
Kuslich SD, Ulstrom CL, Michael CJ. The tissue origin of low back pain and sciatica: A report of pain response to tissue stimulation during operation on the lumbar spine using local anesthesia. Orthop Clin North Am. 1991; 22: 181–187.
9.
Solecki L. Studies of farmers’ annual exposure to whole body vibration on selected family farms of mixed production profile. Ann Agric Environ Med. 2012; 19(2): 247–253.
10.
Bergier J. Studies and measurements of physical activity of the society. Ann Agric Environ Med. 2012; 19(3): 329–331.
11.
Breivik H, Collet B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. E J Pain 2006; 10: 287–333.
12.
Świerkot J. Bóle krzyża – etiologia, diagnostyka i leczenie. Przeg Lek 2006;2:86–98.
13.
Reolofs PDDM, Deyo RA, Koes BW, Scholten RJPM, van Tulden MW. Nonsteroid anti-inflamatory drugs for low back pain: An update Cochrane review. Spine 2008; 33: 1766–1774.
14.
Brzeziński K. Ból przewlekły w praktyce lekarza rodzinnego. Cz II Ból Receptorowy. Medycyna Ogólna 2003; 9: 1–16 (in Polish).
15.
Chłopicki S., Gryglewski RJ. W poszukiwaniu lepszej aspiryny. Medycyna Po Dyplomie 2000, 4–13 (in Polish).
16.
Korbut R, Olszanecki R. Farmakologia niesteroidowych leków przeciwzapalnych. In: Dobrogowski J, Wordliczek J. Medycyna bólu. PZWL, 2004 (in Polish).
17.
Wordliczek J, Dobrogowski J. Kliniczne zastosowanie niesteroidowych leków przeciwzapalnych. In: Dobrogowski J, Wordliczek J. Medycyna bólu. PZWL, 2004 (in Polish).
18.
Fullen BM, Baxter GD, O`Donovan BGG, Doody C, Daly L, Hurly DA. Doctors` attitudes and beliefs regarding acute low back pain management: A systemic review. Pain 2008; 136: 388–396.
19.
Lamot L, Bukovac LT, Vidovic M, Frleta M, Harjacek M. The ‘headto-head’ comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2011;1:131–139.
20.
Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health 2011; 14: 652–656.
21.
Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010; 10: 935–945.
22.
Carabaza A, Cabre F, Garcia AM. et al. Stereoselective inhibition of rat brain cyclooxygenase by dexketoprofen. Chirality 1997; 9:281–285.
23.
Cabre F, Frnandez MF, Calvo I, et al. Analgesic, antiinflamatory, and antipyretic effects of S(+)-ketoprofen in vivo. J Clin Pharmacol 1998;38:3–10.
24.
Kovacs FM, Abraira V, Zamora J, Fernandez C. Spanish Back Pain Research Network. The transition from acute to subacute and chronic low back pain: a study based on determinants of quality of life and prediction of chronic disability. Spine 2005; 30: 1786–1792.
25.
Airaksinen O, Brox JI, Cedraschi C, Hildebrandt J, Klaber-Moffett J, Kovacs F, Mannion AF, Reis S, Staal JB, Ursin H, Zanoli G. Chapter 4 European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006; 15(2): 192–300.
26.
van Tulder M, Koes B. Chronic low back pain. in Evidence-based chronic pain management. Edited by Stannard CF, Kalso E, Ballantyne J. Wiley-Blackwell 2010.
27.
Holmberg SA, Thelin AG. Predictors of sick leave owing to neck or low back pain: a 12-year longitudinal cohort study in a rural male population. Ann Agric Environ Med. 2010;17(2): 251–7.
28.
Fredheim OMS, Fayers P, Saltnes T, Jordhøy M, Borchgrevink PC. Chronic non-malignant pain patients report as poor health-related quality of life as palliative cancer patients. Acta Anaesthesiol Scand. 2008; 52: 143–148.
29.
Ekman M, Jonhagen S, Hunsche E, Jonsson L. Burden of illness of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting. Spine 2005; 30: 1777–1785.
30.
Bączyk M, Bączyk E, Kotlińska-Lemiaszek A, Łuczak J. Ból kostny. Rola niesterydowych leków przeciwzapalnych w terapii bólu kostnego. Nowa Medycyna 2003; 121: 82–85 (in Polish).
31.
Cook AJ, Chastain DC. The classification of patients with chronic pain: age and sex differences. Pain Res Manag. 2001; 6: 142–152.
32.
Leppert W, Łuczak J. Leki w medycynie paliatywnej: Rola tramadolu w leczeniu bólu nowotworowego. Polska Medycyna Paliatywna 200;1:93– 105 (in Polish).
33.
Dobrowolna P, Hagner W. Epidemiologia zespołów bólowych kręgosłupa u pielęgniarek w szpitalu uniwersyteckim im. A. Jurasza w Bydgoszczy oraz biomechaniczna analiza problemu. Med Biol Sci 2007; 21: 53–63 (in Polish).
35.
van Tulder M, Becker A, Bekkering T, Breen A, Gil del Real MT. Hutchinson A, Koes B, Laerum E, Malmivaara A. Chapter 3 European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J. 2006; 2: 169–191.
36.
Ng KF, Tsiu SL, Chan WS. Prevalence of common chronic pain in Hong Kong adults. Clin J Pain. 2002; 18: 275–281.
37.
Rustoen T, Wahl AK, Hanestad BR, Lerdal A, Paul S, Miaskowski C. Gender differences in chronic pain--findings from a population-based study of Norwegian adults. Pain Manag Nurs 2004; 5: 105–117.
38.
Sa KN, Baptista AF, Matos MA, Lessa I. Chronic pain and gender in Salvador population, Brasil. Pain 2008; 139: 498–506.
39.
Brinkhaus B, Witt C, Jena S,Linde K,Streng A, Wagenpfeil S. Inrich D, Walther H-U, Melcjart D, Willich S. Acupuncture in patients with chronic low back pain. Arch Intern Med. 2006; 166: 450–457.
40.
Cherkin DC, Sherman KJ, Avins AL, Erro MP, Ichikawa L, Barlow WE, Delaney K, Hawkes R, Hamilton L, Pressman A, Khalsa PS, Deyo RA. A Randomized Trial Comparing Acupuncture, Simulated Acupuncture, and Usual Care for Chronic Low Back Pain. Arch Intern Med. 2009; 11: 858–866.
41.
Cook AJ, Chastain DC. The classification of patients with chronic pain: age and sex differences. Pain Res Manag. 2001; 6: 142–153.
42.
McEwan, J, Luca MD, Casini A, Gich I, Barbanoj MJ, Tost D, Artigas R, Mauleon D. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol. 1998; 38: 41–45.
43.
Baltron J., Martin-Mola E., Figueroa M., Granados J., Sanmatri R., Argitas R., Torres F., Forns M., Mauleon D. Comparison of dexketoprofen trometamol and ketoprofen in the treatment of osteoarthritis of the knee. J Clin Pharmacol. 1998; 38: 74–80.
44.
Gaitan G., Herrero JF. Subanalgesic doses of dexketoprofen and HGT-2037 (nitrodexketoprofen) enhance fentanyl antinociception in monoarthric rats. Pharmacol Biochem Behav 2005; 80: 327–332.
45.
Rodríguez MJ, Contreras D, Gálvez R, Castro A, Camba MA, Busquets C, Herrera J. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 2003; 104: 103–110.
46.
Mazario J, Roza C, Herrero JF. The NSAID dexketoprofen is as potent as mu-opioids in the depression of wind-up spinal cord nociceptive reflexes in normal rates. Brain Res. 1999; 816: 512–517.
47.
Moore RA, Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clinical Pharmacology 2008; 8: 11.
48.
Zippel H, Wagenitz A. A Multicentre, Randomised, Double-Blind Study Comparing the Efficacy and Tolerability of Intramuscular Dexketoprofen versus Diclofenac in the Symptomatic Treatment of Acute Low Back Pain. Clin Drug Invest 2007; 27: 533–543.
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.